Literature DB >> 33892137

Alpha defensin-1 attenuates surgically induced osteoarthritis in association with promoting M1 to M2 macrophage polarization.

J W Xie1, Y Wang2, K Xiao3, H Xu4, Z Y Luo5, L Li6, F X Pei7, V B Kraus8, Z Y Huang9.   

Abstract

OBJECTIVE: Macrophages play an important part in the pathogenesis of osteoarthritis (OA). Our objective was to determine the effects of α-defensin-1 on macrophage polarization and consequently OA.
METHODS: OA synovial tissue and synovial fluid were assessed for the presence of M1 (CD68+CD16+CD206-) and M2 (CD68+CD206+CD16-) macrophages by flow cytometry. M0, M1, and M2 macrophages were co-cultured with OA chondrocytes to determine their influence on chondrogenic phenotype. Polarization of THP-1 activated monocytes from M1 to M2 in response to α-defensin-1 was evaluated by flow cytometry, RT-PCR and RNA sequencing. Effects of intra-articular α-defensin-1 in vivo were evaluated in a rat meniscal/ligamentous injury (MLI) model.
RESULTS: The quantity of M1 exceeded M2 polarized macrophages in human OA synovial tissue (mean difference 26.1% [13.6-38.6%], P < 0.001) and fluid (mean difference 10.5% [5.0-16.1%], P = 0.003). M1 to M2 polarization in vitro was most effectively promoted with 10 ng/mL α-defensin-1. Compared with untreated macrophages, the α-defensin-1 polarized macrophages modified co-cultured OA chondrocytes from a pro-catabolic state to a pro-anabolic (regenerative-like) state based on expression of COL2A1, ACN, MMP3, MMP13 and ADAMTS5. Intra-articular α-defensin-1 decreased severity of cartilage damage and synovitis in the MLI rat model. RNAseq analyses suggested insulin and Toll-like receptor signaling pathways in the chondroprotective α-defensin-1 mechanism of action.
CONCLUSION: α-defensin-1 promotes M1 to M2 macrophage polarization in vitro, has beneficial effects on chondrocytes indirectly via M2 macrophage polarization, and attenuates the severity of OA in vivo, suggesting it might be a candidate treatment for OA.
Copyright © 2021 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chondroprotection; Inflammation; Macrophage; Osteoarthritis; Polarization; α-Defensin-1

Mesh:

Substances:

Year:  2021        PMID: 33892137     DOI: 10.1016/j.joca.2021.04.006

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  5 in total

Review 1.  Obesity, Inflammation, and Immune System in Osteoarthritis.

Authors:  Udhaya Nedunchezhiyan; Ibin Varughese; Antonia RuJia Sun; Xiaoxin Wu; Ross Crawford; Indira Prasadam
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

Review 2.  Monocytes, Macrophages, and Their Potential Niches in Synovial Joints - Therapeutic Targets in Post-Traumatic Osteoarthritis?

Authors:  Patrick Haubruck; Marlene Magalhaes Pinto; Babak Moradi; Christopher B Little; Rebecca Gentek
Journal:  Front Immunol       Date:  2021-11-04       Impact factor: 7.561

Review 3.  Exosomes rewire the cartilage microenvironment in osteoarthritis: from intercellular communication to therapeutic strategies.

Authors:  Yuangang Wu; Jiao Li; Yi Zeng; Wenchen Pu; Xiaoyu Mu; Kaibo Sun; Yong Peng; Bin Shen
Journal:  Int J Oral Sci       Date:  2022-08-05       Impact factor: 24.897

Review 4.  Phenotype Diversity of Macrophages in Osteoarthritis: Implications for Development of Macrophage Modulating Therapies.

Authors:  Nataliya V Mushenkova; Nikita G Nikiforov; Nikolay K Shakhpazyan; Varvara A Orekhova; Nikolay K Sadykhov; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

5.  Anti-inflammatory and immunomodulatory effects of the extracellular vesicles derived from human umbilical cord mesenchymal stem cells on osteoarthritis via M2 macrophages.

Authors:  Kanglu Li; Guohua Yan; Hanji Huang; Mingjun Zheng; Ke Ma; Xiaofei Cui; Dejie Lu; Li Zheng; Bo Zhu; Jianwen Cheng; Jinmin Zhao
Journal:  J Nanobiotechnology       Date:  2022-01-20       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.